Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay

Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay

Background Cerebrospinal fluid (CSF) biomarker amyloid‐β1–42 (Abeta42), quantified using the Elecsys® Abeta42 (Gen 1) immunoassay, supports diagnosis of Alzheimer’s disease. Compared with Gen1, the updated assay Elecsys Abeta42 CSF II (Gen2) has a higher threshold for biotin interference, extended m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2020-12, Vol.16, p.n/a
Hauptverfasser: Blennow, Kaj, Zetterberg, Henrik, Rutz, Sandra, Wittig, Martina, Manuilova, Ekaterina, Logan, Chad, Bauer, Ekaterina, Stomrud, Erik
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue
container_start_page
container_title Alzheimer's & dementia
container_volume 16
creator Blennow, Kaj
Zetterberg, Henrik
Rutz, Sandra
Wittig, Martina
Manuilova, Ekaterina
Logan, Chad
Bauer, Ekaterina
Stomrud, Erik
description Background Cerebrospinal fluid (CSF) biomarker amyloid‐β1–42 (Abeta42), quantified using the Elecsys® Abeta42 (Gen 1) immunoassay, supports diagnosis of Alzheimer’s disease. Compared with Gen1, the updated assay Elecsys Abeta42 CSF II (Gen2) has a higher threshold for biotin interference, extended measuring range, and is re‐standardised according to certified reference Abeta42 peptide ERM‐DA480/‐481/‐482. The new Routine‐Use (RU) pre‐analytical protocol will be introduced with the Gen2 assay (reported separately). Here, we present the analytical performance of the Gen2 assay, including comparisons with Gen1. Method Analytical performance experiments were conducted on cobas e 601 analysers. Precision was investigated according to Clinical and Laboratory Standards Institute EP05‐A3 (21‐day experiment) using seven native and two control samples. For lot and instrument comparisons (cobas e 801 vs e 601), 125 native CSF sample pools were measured in one run. Gen1 and Gen2 were compared in two method comparison (MC) studies: in‐house study: 103 frozen CSF samples were measured in one run; external study (Pre‐analytical study 2): CSF samples from 24 patients with suspected normal pressure hydrocephalus were prospectively collected according to the RU, Roche Trial and BioFINDER protocols. MC was based on mean concentrations obtained from 3–4 aliquots per patient. Aliquot‐aliquot variability was compared for each protocol. MC analyses included calculation of Pearson’s correlation (r) and Passing‐Bablok regression fit. Result Precision analysis provided within‐run variability of
doi_str_mv 10.1002/alz.047517
format Article
fullrecord <record><control><sourceid>wiley</sourceid><recordid>TN_cdi_wiley_primary_10_1002_alz_047517_ALZ047517</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ALZ047517</sourcerecordid><originalsourceid>FETCH-LOGICAL-u787-b1420c6e179345f9a87d450ec70bf96dc4a4e7e2f948dbd66d31669cc839b2f43</originalsourceid><addsrcrecordid>eNo9kMtOwzAURC0EEqWw4Qv8AaTYjh_xMqqgIFVi0xWb6Ma-oUZuWuJEVfh6WoJYzWg0OotDyD1nC86YeIT4vWDSKG4uyIwrJTIljL3875pdk5uUPhmTrOBqRr7KFuLYBweRui104HrsQjoNie4b2m-RDgcPPXqKEV0aEy1r7EEKusKWCgopwfhAQ-vi4EP7Qd1-d4ATYt8megz99pdx_vLpe0uuGogJ7_5yTjbPT5vlS7Z-W70uy3U2mMJkNZeCOY3c2FyqxkJhvFQMnWF1Y7V3EiQaFI2Vha-91j7nWlvnitzWopH5nPAJewwRx-rQhR10Y8VZdRZVnURVk6iqXL9PLf8Br_Besw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Blennow, Kaj ; Zetterberg, Henrik ; Rutz, Sandra ; Wittig, Martina ; Manuilova, Ekaterina ; Logan, Chad ; Bauer, Ekaterina ; Stomrud, Erik</creator><creatorcontrib>Blennow, Kaj ; Zetterberg, Henrik ; Rutz, Sandra ; Wittig, Martina ; Manuilova, Ekaterina ; Logan, Chad ; Bauer, Ekaterina ; Stomrud, Erik</creatorcontrib><description>Background Cerebrospinal fluid (CSF) biomarker amyloid‐β1–42 (Abeta42), quantified using the Elecsys® Abeta42 (Gen 1) immunoassay, supports diagnosis of Alzheimer’s disease. Compared with Gen1, the updated assay Elecsys Abeta42 CSF II (Gen2) has a higher threshold for biotin interference, extended measuring range, and is re‐standardised according to certified reference Abeta42 peptide ERM‐DA480/‐481/‐482. The new Routine‐Use (RU) pre‐analytical protocol will be introduced with the Gen2 assay (reported separately). Here, we present the analytical performance of the Gen2 assay, including comparisons with Gen1. Method Analytical performance experiments were conducted on cobas e 601 analysers. Precision was investigated according to Clinical and Laboratory Standards Institute EP05‐A3 (21‐day experiment) using seven native and two control samples. For lot and instrument comparisons (cobas e 801 vs e 601), 125 native CSF sample pools were measured in one run. Gen1 and Gen2 were compared in two method comparison (MC) studies: in‐house study: 103 frozen CSF samples were measured in one run; external study (Pre‐analytical study 2): CSF samples from 24 patients with suspected normal pressure hydrocephalus were prospectively collected according to the RU, Roche Trial and BioFINDER protocols. MC was based on mean concentrations obtained from 3–4 aliquots per patient. Aliquot‐aliquot variability was compared for each protocol. MC analyses included calculation of Pearson’s correlation (r) and Passing‐Bablok regression fit. Result Precision analysis provided within‐run variability of &lt;6% and intermediate precision of &lt;8% for all samples. Measurements of three lots were highly correlated (r=1.00) with bias &lt;5.2%, within the clinically relevant range. Measurements on cobas e 601 and e 801 analysers were highly correlated (r=0.995) and regression analysis yielded a slope of 0.941. Gen1 and Gen2 were strongly correlated in both MC studies (in‐house: r=0.999; external: r=0.990). Slope estimates were 0.75 and 0.79 in the in‐house and external studies, respectively (Figure). Aliquot‐aliquot variability was similar for Gen1 and Gen2 assays within each protocol and lower in the RU versus the Roche Trial protocols (Table). Conclusion The Abeta42 Gen2 assay strongly correlated with the Gen1 assay. High precision and low variability between lots and analysers showed the Gen2 assay provided additional benefits over Gen1 without compromising technical performance.</description><identifier>ISSN: 1552-5260</identifier><identifier>EISSN: 1552-5279</identifier><identifier>DOI: 10.1002/alz.047517</identifier><language>eng</language><ispartof>Alzheimer's &amp; dementia, 2020-12, Vol.16, p.n/a</ispartof><rights>2020 the Alzheimer's Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Falz.047517$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Falz.047517$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Blennow, Kaj</creatorcontrib><creatorcontrib>Zetterberg, Henrik</creatorcontrib><creatorcontrib>Rutz, Sandra</creatorcontrib><creatorcontrib>Wittig, Martina</creatorcontrib><creatorcontrib>Manuilova, Ekaterina</creatorcontrib><creatorcontrib>Logan, Chad</creatorcontrib><creatorcontrib>Bauer, Ekaterina</creatorcontrib><creatorcontrib>Stomrud, Erik</creatorcontrib><title>Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay</title><title>Alzheimer's &amp; dementia</title><description>Background Cerebrospinal fluid (CSF) biomarker amyloid‐β1–42 (Abeta42), quantified using the Elecsys® Abeta42 (Gen 1) immunoassay, supports diagnosis of Alzheimer’s disease. Compared with Gen1, the updated assay Elecsys Abeta42 CSF II (Gen2) has a higher threshold for biotin interference, extended measuring range, and is re‐standardised according to certified reference Abeta42 peptide ERM‐DA480/‐481/‐482. The new Routine‐Use (RU) pre‐analytical protocol will be introduced with the Gen2 assay (reported separately). Here, we present the analytical performance of the Gen2 assay, including comparisons with Gen1. Method Analytical performance experiments were conducted on cobas e 601 analysers. Precision was investigated according to Clinical and Laboratory Standards Institute EP05‐A3 (21‐day experiment) using seven native and two control samples. For lot and instrument comparisons (cobas e 801 vs e 601), 125 native CSF sample pools were measured in one run. Gen1 and Gen2 were compared in two method comparison (MC) studies: in‐house study: 103 frozen CSF samples were measured in one run; external study (Pre‐analytical study 2): CSF samples from 24 patients with suspected normal pressure hydrocephalus were prospectively collected according to the RU, Roche Trial and BioFINDER protocols. MC was based on mean concentrations obtained from 3–4 aliquots per patient. Aliquot‐aliquot variability was compared for each protocol. MC analyses included calculation of Pearson’s correlation (r) and Passing‐Bablok regression fit. Result Precision analysis provided within‐run variability of &lt;6% and intermediate precision of &lt;8% for all samples. Measurements of three lots were highly correlated (r=1.00) with bias &lt;5.2%, within the clinically relevant range. Measurements on cobas e 601 and e 801 analysers were highly correlated (r=0.995) and regression analysis yielded a slope of 0.941. Gen1 and Gen2 were strongly correlated in both MC studies (in‐house: r=0.999; external: r=0.990). Slope estimates were 0.75 and 0.79 in the in‐house and external studies, respectively (Figure). Aliquot‐aliquot variability was similar for Gen1 and Gen2 assays within each protocol and lower in the RU versus the Roche Trial protocols (Table). Conclusion The Abeta42 Gen2 assay strongly correlated with the Gen1 assay. High precision and low variability between lots and analysers showed the Gen2 assay provided additional benefits over Gen1 without compromising technical performance.</description><issn>1552-5260</issn><issn>1552-5279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNo9kMtOwzAURC0EEqWw4Qv8AaTYjh_xMqqgIFVi0xWb6Ma-oUZuWuJEVfh6WoJYzWg0OotDyD1nC86YeIT4vWDSKG4uyIwrJTIljL3875pdk5uUPhmTrOBqRr7KFuLYBweRui104HrsQjoNie4b2m-RDgcPPXqKEV0aEy1r7EEKusKWCgopwfhAQ-vi4EP7Qd1-d4ATYt8megz99pdx_vLpe0uuGogJ7_5yTjbPT5vlS7Z-W70uy3U2mMJkNZeCOY3c2FyqxkJhvFQMnWF1Y7V3EiQaFI2Vha-91j7nWlvnitzWopH5nPAJewwRx-rQhR10Y8VZdRZVnURVk6iqXL9PLf8Br_Besw</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Blennow, Kaj</creator><creator>Zetterberg, Henrik</creator><creator>Rutz, Sandra</creator><creator>Wittig, Martina</creator><creator>Manuilova, Ekaterina</creator><creator>Logan, Chad</creator><creator>Bauer, Ekaterina</creator><creator>Stomrud, Erik</creator><scope/></search><sort><creationdate>202012</creationdate><title>Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay</title><author>Blennow, Kaj ; Zetterberg, Henrik ; Rutz, Sandra ; Wittig, Martina ; Manuilova, Ekaterina ; Logan, Chad ; Bauer, Ekaterina ; Stomrud, Erik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-u787-b1420c6e179345f9a87d450ec70bf96dc4a4e7e2f948dbd66d31669cc839b2f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blennow, Kaj</creatorcontrib><creatorcontrib>Zetterberg, Henrik</creatorcontrib><creatorcontrib>Rutz, Sandra</creatorcontrib><creatorcontrib>Wittig, Martina</creatorcontrib><creatorcontrib>Manuilova, Ekaterina</creatorcontrib><creatorcontrib>Logan, Chad</creatorcontrib><creatorcontrib>Bauer, Ekaterina</creatorcontrib><creatorcontrib>Stomrud, Erik</creatorcontrib><jtitle>Alzheimer's &amp; dementia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blennow, Kaj</au><au>Zetterberg, Henrik</au><au>Rutz, Sandra</au><au>Wittig, Martina</au><au>Manuilova, Ekaterina</au><au>Logan, Chad</au><au>Bauer, Ekaterina</au><au>Stomrud, Erik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay</atitle><jtitle>Alzheimer's &amp; dementia</jtitle><date>2020-12</date><risdate>2020</risdate><volume>16</volume><epage>n/a</epage><issn>1552-5260</issn><eissn>1552-5279</eissn><abstract>Background Cerebrospinal fluid (CSF) biomarker amyloid‐β1–42 (Abeta42), quantified using the Elecsys® Abeta42 (Gen 1) immunoassay, supports diagnosis of Alzheimer’s disease. Compared with Gen1, the updated assay Elecsys Abeta42 CSF II (Gen2) has a higher threshold for biotin interference, extended measuring range, and is re‐standardised according to certified reference Abeta42 peptide ERM‐DA480/‐481/‐482. The new Routine‐Use (RU) pre‐analytical protocol will be introduced with the Gen2 assay (reported separately). Here, we present the analytical performance of the Gen2 assay, including comparisons with Gen1. Method Analytical performance experiments were conducted on cobas e 601 analysers. Precision was investigated according to Clinical and Laboratory Standards Institute EP05‐A3 (21‐day experiment) using seven native and two control samples. For lot and instrument comparisons (cobas e 801 vs e 601), 125 native CSF sample pools were measured in one run. Gen1 and Gen2 were compared in two method comparison (MC) studies: in‐house study: 103 frozen CSF samples were measured in one run; external study (Pre‐analytical study 2): CSF samples from 24 patients with suspected normal pressure hydrocephalus were prospectively collected according to the RU, Roche Trial and BioFINDER protocols. MC was based on mean concentrations obtained from 3–4 aliquots per patient. Aliquot‐aliquot variability was compared for each protocol. MC analyses included calculation of Pearson’s correlation (r) and Passing‐Bablok regression fit. Result Precision analysis provided within‐run variability of &lt;6% and intermediate precision of &lt;8% for all samples. Measurements of three lots were highly correlated (r=1.00) with bias &lt;5.2%, within the clinically relevant range. Measurements on cobas e 601 and e 801 analysers were highly correlated (r=0.995) and regression analysis yielded a slope of 0.941. Gen1 and Gen2 were strongly correlated in both MC studies (in‐house: r=0.999; external: r=0.990). Slope estimates were 0.75 and 0.79 in the in‐house and external studies, respectively (Figure). Aliquot‐aliquot variability was similar for Gen1 and Gen2 assays within each protocol and lower in the RU versus the Roche Trial protocols (Table). Conclusion The Abeta42 Gen2 assay strongly correlated with the Gen1 assay. High precision and low variability between lots and analysers showed the Gen2 assay provided additional benefits over Gen1 without compromising technical performance.</abstract><doi>10.1002/alz.047517</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1552-5260
ispartof Alzheimer's & dementia, 2020-12, Vol.16, p.n/a
issn 1552-5260
1552-5279
language eng
recordid cdi_wiley_primary_10_1002_alz_047517_ALZ047517
source Wiley Online Library Journals Frontfile Complete
title Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A21%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analytical%20characteristics%20of%20the%20updated%20elecsys%20Abeta42%20Gen%202%20assay,%20including%20comparisons%20with%20the%20Gen%201%20assay&rft.jtitle=Alzheimer's%20&%20dementia&rft.au=Blennow,%20Kaj&rft.date=2020-12&rft.volume=16&rft.epage=n/a&rft.issn=1552-5260&rft.eissn=1552-5279&rft_id=info:doi/10.1002/alz.047517&rft_dat=%3Cwiley%3EALZ047517%3C/wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true